TODAY'S HEADLINES

FDA approves novel kidney disease drug

After initially rejecting this drug for chronic kidney disease earlier this year because of manufacturing concerns, FDA approved the drug 4 months ahead of its new timeline. Read more

New hypertension drug gets FDA approval

The first and only fixed-dose combination of a beta blocker and angiotensin II receptor blocker for hypertension will be available in the United States in the second half of this year. Read more

CONTINUING PHARMACY EDUCATION

The rundown: Management of acute and chronic diarrhea

This month's CE activity, "The rundown: Management of acute and chronic diarrhea," is open for pharmacists and pharmacy technicians.
The goal of this activity is to review the various risk factors, etiologies, and treatments of diarrhea as well as the pharmacist's role in its management.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

FDA approves rare liver disease drug

FDA recently granted accelerated approval for obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis. Why the drug is needed

June 24, 2016

Related Articles

FDA approves Veltassa to treat hyperkalemia

FDA grants priority review to heart failure drug